Objective: The objective was to assess the risk of aneurysmal subarachnoid hemorrhage (aSAH) in the initial 15 years after negative aneurysm screening in persons with one first-degree relative with aSAH.Methods: From a cohort of first-degree relatives of patients with aSAH who underwent screening between 1995 and 1997 (n 5 626), we included those with a negative screening (n 5 601). We retrieved all causes of death and sent a questionnaire to screenees who were still alive. If aSAH was reported, we reviewed all medical data. We assessed the incidence of aSAH in this cohort with survival analysis and calculated an incidence ratio by dividing the observed incidence with the age-and sex-adjusted incidence in the general population.Results: Of the 601 screenees, 3 had aSAH during 8,938 follow-up patient-years (mean 14.9 years). After 15 years, the cumulative incidence was 0.50% (95% confidence interval: 0.00%-1.06%) with an incidence rate of 33.6 per 100,000 person-years; the incidence rate ratio was 1.7 (95% confidence interval: 0.3-5.7).Conclusions: In the first 15 years after a negative screening, the risk of aSAH in persons with one first-degree relative with aSAH is not nil, but in the range of that in the general population, or even higher. Whether this finding justifies serial aneurysm screening in this population requires further study. A familial preponderance is a strong risk factor for the development of intracranial aneurysms. Persons with 2 or more affected first-degree relatives have a 50 times higher risk of having an aneurysmal subarachnoid hemorrhage (aSAH) during life, 1 and in such relatives, repeated screening is cost-effective.2 Persons with only one affected first-degree relative have a 2-timeshigher risk of aSAH compared with the general population.1 There is some evidence that familial intracranial aneurysms have a greater rupture risk compared with sporadic aneurysms.3 In a Markov model based on observational data from screening 626 first-degree relatives of a consecutive series of patients with aSAH between 1995 and 1997, we found that a single magnetic resonance angiographic (MRA) screening for intracranial aneurysms increased life expectancy slightly. However, this increase was at the cost of a reduced number of life years in good health because of complications of preventive treatment and thus screening was not effective. On average, screening and preventive treatment increased estimated life expectancy by 0.9 months per person screened, at the expense of 19 years of impaired functional health per person. 4 Also, screening was not considered to be efficient because 149 relatives would need to be screened to prevent a subarachnoid hemorrhage in one person on a lifetime basis.However, in the model, it was assumed that persons with a negative screen were no longer at risk of aSAH, but empirical data supporting this assumption are lacking.